A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2017
At a glance
- Drugs SPX 101 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Spyryx Biosciences
- 01 Sep 2017 Status changed from recruiting to completed.
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.
- 21 Feb 2017 New trial record